By contrast, the progression rate of American SCA3 patients in the Clinical Research Consortium for Spinocerebellar Ataxias (CRC‐SCA) study was somewhat slower with a mean yearly increase of 0.65 points.7 This evidence concerns the gene ATXN3 and autosomal dominant cerebellar ataxia.